Board-level scientific advisory — biologics and vaccines
Former Biologics R&D Executive at Lonza, Sanofi, Johnson & Johnson, Crucell
Independent review of biologics R&D strategy, portfolio priorities, and scientific rationale.
“Is the evidence behind this program strong enough to take it to the next stage?”
Proof-of-concept research from promise to evidence.
“Our lead program missed its endpoint. Is it the biology or the execution?”
Assessment of immunology, vaccine, and antibody platform opportunities.
“We are being asked to invest in an antibody platform. What would make us go for it?”
For Biotech leadership Pharma R&D teams Boards and investors
Guidance on the science, organisation and strategy a successful and innovative biologics enterprise requires. Based in France.
Responsible for global biologics R&D: discovery, design and development of biologics platforms, processes and technologies across Europe and the US.
Biologics Research platform activities in Europe and the US — discovery, design and production of novel biologics and nucleic acids for the R&D portfolio, and the technologies behind them.